米国企業
Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.CTXR

時価総額

$9066.8万

PER

	2011年 9月30日	2012年 9月30日	2013年 9月30日	2015年 9月30日	2016年 9月30日	2018年 9月30日	2019年 9月30日	2020年 9月30日	2021年 9月30日	2022年 9月30日
Net Loss	-26,341	-22,006	-31,369	-2,902,268	-8,295,698	-12,536,638	-15,562,144	-17,548,085	-23,054,434	-33,640,646
Stock-based compensation – general and administrative	-	-	-	486,271	732,151	779,701	715,983	803,261	1	4
Issuance of common stock for services	-	-	-	-	-	-	-	528,770	68,000	378,204
Amortization of operating lease right-of-use asset	-	-	-	-	-	-	-	-	-	176,754
Depreciation	-	-	-	-	1,343	1,753	893	844	1,492	2,923
Deferred income tax expense	-	-	-	-	-	-	-	-	-	576,000
Gain from forgiveness of notes payable – paycheck protection program and accrued interest	-	-	-	-	-	-	-	-	166,557	-
Prepaid expenses	-	-	-	-60,000	-40,759	-162,514	-9,621	74,126	3	111,176
Deposits	-	-	-	-	-	-	-	-	19,031	-
Accounts payable	906	-	11,474	452,981	105,230	971,013	1	-857,307	-579,140	-111,717
Accrued expenses	3,950	4,150	2,700	-52,057	351,182	70,739	64,568	-82,185	457,920	783,434
Accrued compensation	-	-	-	-	-	135,915	201,773	254,231	251,081	-143,749
Accrued interest	-	-	-	7,500	7,009	-15,645	-16,443	-15,673	87,996	-
Operating lease liability	-	-	-	-	-	-	-	-123,254	-158,999	-177,237
Net Cash Used In Operating Activities	-20,781	-20,324	-20,604	-2,385,416	-5,900,421	-11,318,138	-12,437,751	-16,930,658	-24,250,414	-28,361,256
Purchase of property and equipment	-	-	-	-	-	-	-	1,831	6,938	-
Net Cash Used In Investing Activities	-	-	-	-	255,748	-	-	-1,831	-40,006,938	-
Principal paid on notes payable – related parties	-	-	-	-	600,000	-	-	-	172,970	-
Proceeds from sale of NoveCite, Inc. common stock	18,000	18,000	18,000	-	-	-	-	-	82,634	-
Net proceeds from private placement	-	-	-	2	5	-	-	-	18	-
Net Cash Provided By Financing Activities	36,493	56,740	77,209	2	5	17	11	23	120	-
Net Change in Cash and Cash Equivalents	-	-	-	-	-	-	-	6	56	-28,361,256